SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

Clinical trials for SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) explained in plain language.

Never miss a new study

Get alerted when new SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) trials appear

Sign up with your email to follow new studies for SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New heart failure drug enters Mid-Stage testing

Disease control Recruiting now

This study is testing an investigational drug called CK-4021586 in adults with a specific type of heart failure where the heart pumps normally but still causes symptoms like shortness of fatigue. The main goals are to find a safe and effective dose and see how the body processes …

Matched conditions: SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

Phase: PHASE2 • Sponsor: Cytokinetics • Aim: Disease control

Last updated Mar 23, 2026 15:16 UTC

SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

Get alerted when new SYMPTOMATIC HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) trials appear

New heart failure drug enters Mid-Stage testing